

BETAMETHASONE DIPROPIONATE- betamethasone dipropionate cream
Cosette Pharmaceuticals, Inc.

BETAMETHASONE DIPROPIONATE CREAM, USP 0.05%

(Potency expressed as betamethasone)

FOR DERMATOLOGIC USE ONLY


NOT FOR OPHTHALMIC USE

Rx only

DESCRIPTION

Betamethasone Dipropionate Cream USP, 0.05% contains betamethasone dipropionate USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.

Betamethasone dipropionate is a white to almost white powder insoluble in water. Chemically, it is 9-fluoro-11 β ,17,21-trihydroxy-16 β -methylpregna-1,4-diene-3,20-dione 17,21-dipropionate. The structural formula is:



Molecular Formula: C₂₈H₃₇FO₇

Molecular Weight: 504.60

Each gram of the 0.05% Cream contains 0.64 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone) in a soft, white to off white, hydrophilic cream of purified water, mineral oil, white petrolatum, polyoxyl 20 cetostearyl ether, cetyl alcohol, stearyl alcohol, monobasic sodium phosphate, chlorocresol is present as a preservative. Sodium hydroxide or phosphoric acid solution to adjust pH, if required.

CLINICAL PHARMACOLOGY

Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see DOSAGE AND ADMINISTRATION).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS AND USAGE

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS

General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings (see DOSAGE AND ADMINISTRATION).

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of

the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS—Pediatric Use). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for Patients: Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive.
4. Patients should report any signs of local adverse reactions.
5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings (see DOSAGE AND ADMINISTRATION).

Laboratory tests: The following tests may be helpful in evaluating the HPA axis suppression:

Urinary free cortisol test
ACTH stimulation test

Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities **not** likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS

The following local adverse reactions are reported infrequently when Betamethasone Dipropionate products are used as recommended in the DOSAGE AND ADMINISTRATION section. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infections, skin atrophy, striae and miliaria.

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia and glucosuria in some patients.

To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).

DOSAGE AND ADMINISTRATION

Apply a thin film of Betamethasone Dipropionate Cream to the affected skin areas once daily. In some cases, twice daily dosage may be necessary.

If an infection develops, appropriate antimicrobial therapy should be instituted.

Betamethasone Dipropionate Cream should not be used with occlusive dressings.

HOW SUPPLIED

Betamethasone Dipropionate Cream USP, 0.05% is supplied as follows:

15 g tube (NDC 0713-0659-15)

45 g tube (NDC 0713-0659-37)

Store at 25°C, excursions permitted between 15° and 30°C. Protect from light and freezing.

Distributed by:

Cosette Pharmaceuticals, Inc.

South Plainfield, NJ 07080

Iss. 11/2019

8-0659CPLNC1 GW7381

PRINCIPAL DISPLAY PANEL

NDC 0713-0659-15


Betamethasone Dipropionate Cream, USP 0.05%

15 g

Rx only

FOR DERMATOLOGIC USE ONLY. NOT FOR OPHTHALMIC USE.

Cosette Pharmaceuticals, Inc.





NDC 0713-0659-15

Rx only

**Betamethasone Dipropionate
Cream, USP**

0.05%

15 g

(Potency expressed as betamethasone)
**FOR DERMATOLOGIC USE ONLY.
NOT FOR OPHTHALMIC USE.**

Each gram of the 0.05% Cream contains 0.64 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone) in a soft, white to off white, hydrophilic cream of purified water, mineral oil, white petrolatum, polyoxyl 20 cetostearyl ether, cetyl alcohol, stearyl alcohol, monobasic sodium phosphate; chlorocresol is present as a preservative. Sodium hydroxide or phosphoric acid solution to adjust pH, if required.

Usual Dosage: Apply a thin film of the cream to the affected skin areas once daily. In some cases, twice daily dosage may be necessary. See package insert for full prescribing information. Store at 25°C, excursions permitted between 15°C and 30°C. Protect from light and freezing.

WARNING: Keep out of reach of children.

See crimp of tube for Lot No. and Exp. Date.

IMPORTANT: Do not use if seal has been punctured or is not visible.

TO OPEN: Use cap to puncture seal.

Distributed by:

Cosette Pharmaceuticals, Inc.

South Plainfield, NJ 07080

11-65915CPLNC1 Iss. 11/2019 GW95



F.P.O. 95
Read Direction ↑

NDC 0713-0659-37

Betamethasone Dipropionate Cream, USP 0.05%

45 g

Rx only

FOR DERMATOLOGIC USE ONLY. NOT FOR OPHTHALMIC USE.

Cosette Pharmaceuticals, Inc.



Betamethasone Dipropionate Cream, USP

NDC 0713-0659-37

Rx only

0.05%

45 g

(Potency expressed as betamethasone)

FOR DERMATOLOGIC USE ONLY. NOT FOR OPHTHALMIC USE.

See crimp of tube for Lot No. and Exp. Date.

IMPORTANT: The opening of this product is covered by a metal tamper-resistant seal. If this seal has been punctured or is not visible, do not use and return product to place of purchase.

TO OPEN: To puncture the seal, reverse the cap and place the puncture-top onto the tube. Push down firmly until seal is open.

TO CLOSE: Screw the cap back onto the tube.

Distributed by: Cosette Pharmaceuticals, Inc.

South Plainfield, NJ 07080 10-65937CPLNC1 Iss. 11/2019 GW710269

GTIN 00307130659376



3 0713-0659-37 6



Betamethasone Dipropionate Cream, USP

NDC 0713-0659-37

Rx only

0.05%

45 g

(Potency expressed as betamethasone)

FOR DERMATOLOGIC USE ONLY. NOT FOR OPHTHALMIC USE.

Each gram of the 0.05% Cream contains 0.64 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone) in a soft, white to off white, hydrophilic cream of purified water, mineral oil, white petrolatum, polyoxyl 20 cetostearyl ether, cetyl alcohol, stearyl alcohol, monobasic sodium phosphate; chlorocresol is present as a preservative. Sodium hydroxide or phosphoric acid solution to adjust pH, if required.

Usual Dosage: Apply a thin film of the cream to the affected skin areas once daily. In some cases, twice daily dosage may be necessary. See package insert for full prescribing information.

WARNING: Keep out of reach of children.

Store at 25°C, excursions permitted between 15° and 30°C. Protect from light and freezing.

No Ink
No Coat



710269



710269



Betamethasone Dipropionate Cream, USP

NDC 0713-0659-37

Rx only

0.05%

(Potency expressed as betamethasone)

FOR DERMATOLOGIC USE ONLY. NOT FOR OPHTHALMIC USE.

45 g

Each gram of the 0.05% Cream contains 0.64 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone) in a soft, white to off white, hydrophilic cream of purified water, mineral oil, white petrolatum, polyoxyl 20 cetostearyl ether, cetyl alcohol, stearyl alcohol, monobasic sodium phosphate; chlorocresol is present as a preservative. Sodium hydroxide or phosphoric acid solution to adjust pH, if required.

Usual Dosage: Apply a thin film of the cream to the affected skin areas once daily. In some cases, twice daily dosage may be necessary. See package insert for full prescribing information.

Store at 25°C, excursions permitted between 15°C and 30°C. Protect from light and freezing.

WARNING: Keep out of reach of children.

See crimp of tube for Lot No. and Exp. Date.

IMPORTANT: Do not use if seal has been punctured or is not visible.

TO OPEN: Use cap to puncture seal.

Distributed by: Cosette Pharmaceuticals, Inc.

South Plainfield, NJ 07080

11-65937CPLNC1

Iss. 11/2019

GW1136



FPO 1136
Read Direction ↑

BETAMETHASONE DIPROPIONATE

betamethasone dipropionate cream

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0713-0659
Route of Administration	TOPICAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BETAMETHASONE DIPROPIONATE (UNII: 826Y60901U) (BETAMETHASONE - UNII:9842X06Q6M)	BETAMETHASONE	0.5 mg in 1 g

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	
MINERAL OIL (UNII: T5L8T28FGP)	

PETROLATUM (UNII: 4T6H12BN9U)	
POLYOXYL 20 CETOSTEARYL ETHER (UNII: YRC528SWUY)	
CETYL ALCOHOL (UNII: 936JST6JCN)	
STEARYL ALCOHOL (UNII: 2KR89I4H1Y)	
SODIUM PHOSPHATE, MONOBASIC (UNII: 3980JH2SW)	
CHLOROCRESOL (UNII: 36W5307109)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
PHOSPHORIC ACID (UNII: E4GA8884NN)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0713-0659-15	1 in 1 CARTON	10/12/2018	
1		15 g in 1 TUBE; Type 0: Not a Combination Product		
2	NDC:0713-0659-37	1 in 1 CARTON	10/12/2018	
2		45 g in 1 TUBE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA210217	10/12/2018	

Labeler - Cosette Pharmaceuticals, Inc. (116918230)

Registrant - Cosette Pharmaceuticals, Inc. (116918230)

Establishment

Name	Address	ID/FEI	Business Operations
Cosette Pharmaceuticals NC Laboratories, LLC		079419931	analysis(0713-0659) , label(0713-0659) , manufacture(0713-0659) , pack(0713-0659)

Revised: 4/2022

Cosette Pharmaceuticals, Inc.